Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New trial update on FDA/Multiple melanoma

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron May 03, 2023 6:52pm

142 Views

Post# 35428779

RE:New trial update on FDA/Multiple melanoma

@canadafan. Hello. I must correct you. MM is Multiple Myeloma. Thank you for the pointing this out. I believe both NIH & NCI got added, and I think it is noteworthy. MM is still very much a part of ONC/Y. Best.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market